FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.

Trial Details

NCT ID
NCT07216105
Phase
PHASE1
Sponsor
Fate Therapeutics
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • FT836
  • Paclitaxel
  • Cetuximab
  • Trastuzumab
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • La Jolla, California, United States|32.84727,-117.2742
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • For all regimens, disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemi…
  • Evidence of adequate organ function as determined by all of the following:
  • Absolute neutrophil count (ANC) \>1000/µL without growth factor support within 7 days prior to start of first study intervention
  • Platelet count ≥75,000/µL without transfusion support within 14 days prior to start of first study intervention

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →